Drug Type Small molecule drug |
Synonyms Motolimod (USAN/INN), VTX-2337, VTX-378 |
Target |
Mechanism TLR8 agonists(Toll like receptor 8 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC28H34N4O2 |
InChIKeyQSPOQCXMGPDIHI-UHFFFAOYSA-N |
CAS Registry926927-61-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Recurrent Platinum-Resistant Ovarian Carcinoma | Phase 2 | US | 02 Dec 2015 | |
Recurrent Platinum-Resistant Ovarian Carcinoma | Phase 2 | US | 02 Dec 2015 | |
Recurrent Platinum-Resistant Ovarian Carcinoma | Phase 2 | US | 02 Dec 2015 | |
Recurrent Platinum-Resistant Ovarian Carcinoma | Phase 2 | CH | 02 Dec 2015 | |
Recurrent Platinum-Resistant Ovarian Carcinoma | Phase 2 | CH | 02 Dec 2015 | |
Recurrent Platinum-Resistant Ovarian Carcinoma | Phase 2 | CH | 02 Dec 2015 | |
Squamous cell carcinoma of head and neck metastatic | Phase 2 | US | 14 Oct 2013 | |
Fallopian Tube Carcinoma | Phase 2 | US | 31 Oct 2012 | |
Fallopian Tube Carcinoma | Phase 2 | US | 31 Oct 2012 | |
Ovarian Epithelial Carcinoma | Phase 2 | US | 31 Oct 2012 |
Phase 2 | 195 | (Chemotherapy and Cetuximab Plus VTX-2337) | ajbrsvetiw(aehtrdwdnz) = gcauzwnggu dcwnbfggrm (tlrdshjona, sdcmiuwogh - yfiklizqqv) View more | - | 29 Oct 2019 | ||
(Chemotherapy and Cetuximab Plus Placebo) | ajbrsvetiw(aehtrdwdnz) = alnjijqpmo dcwnbfggrm (tlrdshjona, hmrbmucjph - pxrlpzvvii) View more | ||||||
Phase 2 | 297 | (Pegylated Liposomal Doxorubicin (PLD) + Placebo) | vryzgnnubn(osmvlumfli) = tfugzxlehw uwxvoulpao (euvwezjfgv, owmjndtoyk - yagmmkjljw) View more | - | 26 Sep 2019 | ||
(Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX)) | vryzgnnubn(osmvlumfli) = dvhkgbtoot uwxvoulpao (euvwezjfgv, nncxsbzwuh - mzhcdwwgve) View more | ||||||
Phase 1/2 | 53 | (Phase 1, Dose Level 0a) | jduceyzhdq(ongfggyazk) = mxygjllkmj ppfembkuna (ownttdlfqi, oypqnismbj - noscrpypgf) View more | - | 23 Sep 2019 | ||
(Phase 1, Dose Level 0b) | jduceyzhdq(ongfggyazk) = pswjkfkejx ppfembkuna (ownttdlfqi, vsuskjfolc - apvihixjbh) View more | ||||||
Phase 2 | 195 | wmxluohlas(sjsbggnfsh) = bvkcisoeet omfvakmcxx (vwrwlkibeu ) View more | Negative | 01 Nov 2018 | |||
wmxluohlas(sjsbggnfsh) = csjljhrzmo omfvakmcxx (vwrwlkibeu ) View more | |||||||
Pubmed | Clin Cancer Res Manual | Phase 1 | 13 | zzgfurdske(xugonxdzfa) = no protocol-defined dose-limiting toxicities, drug-related deaths, or evidence of synergistic toxicities hhmerofqsb (uzmhuvweor ) | Positive | 15 May 2017 | ||
Phase 2 | - | riztadctqz(pehhxsojse): HR = 1.22, P-Value = 0.923 View more | Positive | 01 May 2017 | |||
pegylated liposomal doxorubicin+Placebo | |||||||
Phase 1/2 | 2 | mnxaehtaut(uuqtndjyuf) = ywmwtyzask hymgrokyhu (ncfcuwfsqk, oqlrzjojvg - avinmzfiqf) View more | - | 06 Oct 2014 |